By inducing the release of ZOL from the bone matrix with US, it is likely that a single dose of this bisphosphonate (0.1 mg/kg) also inhibited the infiltration of proangiogenic CD11b+ myelomonocytic cells within human breast tumors. This evidence concerns the gene ITGAM and breast neoplasm.